TY - JOUR
T1 - CA-125
T2 - A potential prognostic indicator in patients with cervical cancer?
AU - Goldberg, Gary L.
AU - Sklar, Avi
AU - O'Hanlan, Katherine A.
AU - Levine, Phyllis A.
AU - Runowicz, Carolyn D.
PY - 1990/3
Y1 - 1990/3
N2 - We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and followup CA-125 levels were measured in 64 patients. Fifty-five patients (86%) had squamous cell carcinoma and 9 (14%) had adenocarcinoma of the cervix. At initial presentation 19 (30%) had CA-125 levels >35 U/ml, 12 (19%) had levels of 16-35 U/ml, and 33 (51%) had levels <16 U/ml. Of the 11 patients who had pre- and post-treatment levels >35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.
AB - We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and followup CA-125 levels were measured in 64 patients. Fifty-five patients (86%) had squamous cell carcinoma and 9 (14%) had adenocarcinoma of the cervix. At initial presentation 19 (30%) had CA-125 levels >35 U/ml, 12 (19%) had levels of 16-35 U/ml, and 33 (51%) had levels <16 U/ml. Of the 11 patients who had pre- and post-treatment levels >35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.
UR - http://www.scopus.com/inward/record.url?scp=0025911183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025911183&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(90)90281-O
DO - 10.1016/0090-8258(90)90281-O
M3 - Article
C2 - 2013443
AN - SCOPUS:0025911183
SN - 0090-8258
VL - 40
SP - 222
EP - 224
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -